Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A live attenuated vaccine developed by the Beijing Chaoyang District Centre for Disease Control and Prevention for the prevention of herpes zoster (shingles) in adults aged 50 years and older. The vaccine utilizes a weakened form of the Varicella Zoster Virus (VZV) to stimulate a robust immune response, specifically targeting the decline in cell-mediated immunity associated with aging. By boosting VZV-specific T-cell levels, the vaccine aims to prevent the reactivation of latent VZV from the sensory ganglia. Clinical development has progressed through Phase 1 and Phase 2 trials in China, evaluating the safety and immunogenicity of various viral titers ranging from 4.3 to 5.0 lgPFU.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zoster vaccine live (Beijing Chaoyang District Centre for Disease Control and Prevention).